# Geron Corporation: more meaningful moments

> Geron is a hematology biopharmaceutical company focused on creating more meaningful moments for people living with blood cancer\.

Generated by Yoast SEO v28.6, this is an llms.txt file, meant for consumption by LLMs.

## Pages
- [About Geron](https://www.geron.com/about-geron/)
- [Contact](https://www.geron.com/contact/)
- [Terms of Use](https://www.geron.com/terms-of-use/)
- [Privacy Policy](https://www.geron.com/privacy-policy/)
- [Focus Areas](https://www.geron.com/focus-areas/)
- [Lower\-risk Myelodysplastic Syndromes \(LR\-MDS\)](https://www.geron.com/focus-areas/myelodysplastic-syndromes-lrmds/)
- [Myelofibrosis \(MF\)](https://www.geron.com/focus-areas/myelofibrosis-mf/)
- [Our Medicine](https://www.geron.com/our-medicine/)
- [Science](https://www.geron.com/science/)
- [Telomerase Inhibition](https://www.geron.com/science/telomerase-inhibition/)
- [Clinical Trials](https://www.geron.com/science/clinical-trials/)
- [Leadership](https://www.geron.com/about-geron/leadership/)
- [Careers / Open Positions](https://www.geron.com/about-geron/careers-open-positions/)
- [Glossary of Terms](https://www.geron.com/focus-areas/glossary-of-terms/)
- [News](https://www.geron.com/news/)

## Clinical Trials
- [IMpactMF](https://www.geron.com/clinical-trial/impact-mf/)
- [IMproveMF ](https://www.geron.com/clinical-trial/improvemf/)
- [IMAGINE ](https://www.geron.com/clinical-trial/imagine/)
- [IMpress ](https://www.geron.com/clinical-trial/impress/)

## Events
- [2026 Stifel Virtual Targeted Oncology Forum](https://www.geron.com/event/2026-stifel-virtual-targeted-oncology-forum/)
- [Goldman Sachs 47th Annual Global Healthcare Conference](https://www.geron.com/event/goldman-sachs-47th-annual-global-healthcare-conference/)
- [Q2 2026 Geron Earnings Conference Call](https://www.geron.com/event/q2-2026-geron-earnings-conference-call/)
- [2026 Cantor Global Healthcare Conference](https://www.geron.com/event/2026-cantor-global-healthcare-conference/)
- [H\.C\. Wainwright 28th Annual Global Investment Conference](https://www.geron.com/event/h-c-wainwright-28th-annual-global-investment-conference/)

## Pipeline
- [Frontline MF](https://www.geron.com/pipeline/frontline-mf/)
- [Next Generation TI Program](https://www.geron.com/pipeline/next-generation-ti-program/)
- [LR\-MDS](https://www.geron.com/pipeline/td-lr-mds/)
- [R/R AML](https://www.geron.com/pipeline/r-r-aml/)
- [R/R MF](https://www.geron.com/pipeline/imetelstat-additional-indications/)

## Posters
- [Correlation Between IL\-8 and TNF\-Alpha and Overall Survival in Imetelstat\-Treated Patients With Myelofibrosis Relapsed or Refractory to a Janus\-Associated Kinase Inhibitor in the IMbark Trial](https://www.geron.com/poster/correlation-between-il-8-and-tnf-alpha-and-overall-survival-in-imetelstat-treated-patients-with/)
- [Early Real\-World Use and Hematologic Outcomes With Imetelstat in Patients With Myelodysplastic Syndromes: Insights From a United States Community Oncology Chart Review](https://www.geron.com/poster/early-real-world-use-and-hematologic-outcomes-with-imetelstat-in-patients-with-myelodysplastic-syndromes-insights-from-a-united-states-community-oncology-chart-review/)
- [Updated Analysis of Overall Survival With Imetelstat in Relapsed or Refractory Myelofibrosis from IMbark Versus Real\-World Data, and Assessment of Real\-World Treatment Patterns: Updated Post Hoc Analysis With Extended Follow Up](https://www.geron.com/poster/updated-analysis-of-overall-survival-with-imetelstat-in-relapsed-or-refractory-myelofibrosis-from-imbark-versus-real-world-data-and-assessment-of-real-world-treatment-patterns-updated-post-hoc/)
- [Imetelstat, a Telomerase Inhibitor, Induces Morphologic and Molecular Remissions in Myelofibrosis and Reversal of Bone Marrow Fibrosis](https://www.geron.com/poster/imetelstat-a-telomerase-inhibitor-induces-morphologic-and-molecular-remissions-in-myelofibrosis-and-reversal-of-bone-marrow-fibrosis/)
- [Imetelstat, A Potent Telomerase Inhibitor, Inhibits the Spontaneous Growth of CFU\-Meg In Vitro From Essential Thrombocythemia Patients but Not From Healthy Individuals](https://www.geron.com/poster/imetelstat-a-potent-telomerase-inhibitor-inhibits-the-spontaneous-growth-of-cfu-meg-in-vitro/)

## Press Releases
- [Geron Corporation Announces Oral Presentations Highlighting Imetelstat at International Hematology Congresses in Europe and Asia](https://www.geron.com/press-release/geron-corporation-announces-oral-presentations-highlighting-imetelstat-at-international-hematology-congresses-in-europe-and-asia/)
- [Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635\(c\)\(4\)](https://www.geron.com/press-release/geron-corporation-reports-inducement-grants-under-nasdaq-listing-rule-5635c4/)
- [Geron to Present at Upcoming Investor Conferences](https://www.geron.com/press-release/geron-to-present-at-upcoming-investor-conferences-2/)
- [Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635\(c\)\(4\)](https://www.geron.com/press-release/geron-corporation-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-6/)
- [Geron Announces Appointment of New Members to its Board of Directors](https://www.geron.com/press-release/geron-announces-appointment-of-new-members-to-its-board-of-directors/)

## Publications
- [Telomerase Inhibition With Imetelstat in Patients With Lower\-Risk Myelodysplastic Syndromes: Integrating Molecular Findings, Cytopenias, and Clinical Outcomes](https://www.geron.com/publication/telomerase-inhibition-with-imetelstat-in-patients-with-lower-risk-myelodysplastic-syndromes-integrating-molecular-findings-cytopenias-and-clinical-outcomes/)
- [Durable Clinical Outcomes With Imetelstat \(IME\) in Korean Patients \(Pts\) With Lower\-Risk \(LR\)\-MDS](https://www.geron.com/publication/durable-clinical-outcomes-with-imetelstat-ime-in-korean-patients-pts-with-lower-risk-lr-mds/)
- [Real\-World Experience With Imetelstat in Lower\-Risk Myelodysplastic Syndromes: Insights From United States Claims Data](https://www.geron.com/publication/real-world-experience-with-imetelstat-in-lower-risk-myelodysplastic-syndromes-insights-from-united-states-claims-data/)
- [Combining the Telomerase Inhibitor Imetelstat with the BCL\-2 Inhibitor Venetoclax Enhances Apoptosis and Improves Survival in Acute Myeloid Leukemia Cellular and Animal Models](https://www.geron.com/publication/combining-the-telomerase-inhibitor-imetelstat-with-the-bcl-2-inhibitor-venetoclax-enhances-apoptosis-and-improves-survival-in-acute-myeloid-leukemia-cellular-and-animal-models/)
- [Imetelstat improves patient\-reported outcomes and quality of life in lower\-risk myelodysplastic syndromes: results from the phase III IMerge study](https://www.geron.com/publication/imetelstat-improves-patient-reported-outcomes-and-quality-of-life-in-lower-risk-myelodysplastic-syndromes-results-from-the-phase-iii-imerge-study/)

## Resources
- [Idiopathic myelofibrosis](https://www.geron.com/resource/idiopathic-myelofibrosis/)
- [Understanding Myelofibrosis](https://www.geron.com/resource/myelofibrosis/)
- [Primary myelofibrosis](https://www.geron.com/resource/primary-myelofibrosis/)
- [About myelodysplastic syndromes](https://www.geron.com/resource/about-myelodysplasticsyndromes/)
- [What is MDS?](https://www.geron.com/resource/what-is-mds/)

## Team
- [Dawn C\. Bir](https://www.geron.com/team/dawn-bir/)
- [Constantine Chinoporos](https://www.geron.com/team/constantine-chinoporos/)
- [John F\. McDonald](https://www.geron.com/team/john-mcdonald/)
- [Michelle Robertson](https://www.geron.com/team/michelle-robertson/)
- [Shannon T\. Odam](https://www.geron.com/team/shannon-odam/)

## Terms
- [Transfusion Dependence](https://www.geron.com/focus-areas/glossary-of-terms/)
- [IPSS\-M](https://www.geron.com/geron-term/ipss-m/)
- [Iron Chelation Therapy](https://www.geron.com/geron-term/iron-chelation-therapy/)
- [Study Site](https://www.geron.com/geron-term/study-site/)
- [Bone Marrow Fibrosis](https://www.geron.com/geron-term/bone-marrow-fibrosis/)

## Popups
- [Careers page EEO rights](https://www.geron.com/?post_type=popup&p=2286)

## Popup Themes
- [Framed Border](https://www.geron.com/?post_type=popup_theme&p=131)
- [Floating Bar \- Soft Blue](https://www.geron.com/?post_type=popup_theme&p=132)
- [Content Only \- For use with page builders or block editor](https://www.geron.com/?post_type=popup_theme&p=133)
- [Default Theme](https://www.geron.com/?post_type=popup_theme&p=126)
- [Light Box](https://www.geron.com/?post_type=popup_theme&p=127)

## Focus Areas
- [Lower\-risk Myelodysplastic Syndromes \(LR\-MDS\)](https://www.geron.com/focus-area/lower-risk-myelodysplastic-syndromes-mds/)
- [Myelofibrosis \(MF\)](https://www.geron.com/focus-area/myelofibrosis-mf/)
- [Acute Myeloid Leukemia \(AML\)](https://www.geron.com/focus-area/acute-myeloid-leukemia-aml/)

## Resource Types
- [Clinical Data](https://www.geron.com/resource-type/clinical-data/)
- [Preclinical Data](https://www.geron.com/resource-type/preclinical-data/)
- [Review](https://www.geron.com/resource-type/review/)
- [Real\-World Data](https://www.geron.com/resource-type/real-world-data/)

## Subcategory
- [Real\-world evidence](https://www.geron.com/subcategory/real-world-evidence/)
- [PAG\-created](https://www.geron.com/subcategory/pag-created/)
- [Geron\-created](https://www.geron.com/subcategory/geron-created/)
- [Investigator\-sponsored](https://www.geron.com/subcategory/investigator-sponsored/)
- [Geron\-sponsored](https://www.geron.com/subcategory/geron-sponsored/)

## Team Types
- [Leadership](https://www.geron.com/team-type/leadership/)
- [Board of Directors](https://www.geron.com/team-type/board-of-directors/)

## Term Categories
- [Clinical Trials](https://www.geron.com/term-category/clinical-trials/)
- [Myelodysplastic Syndromes \(MDS\)](https://www.geron.com/term-category/myelodysplastic-syndromes-mds/)
- [Blood cells \& bone marrow](https://www.geron.com/term-category/blood-cells-bone-marrow/)
- [Myelofibrosis \(MF\)](https://www.geron.com/term-category/myelofibrosis-mf/)

## Optional
- [Sitemap index](https://www.geron.com/sitemap_index.xml)